Regeneron Pharmaceuticals (REGN) Net Margin (2009 - 2026)

Regeneron Pharmaceuticals' Net Margin history runs 18 years deep, the most recent figure standing at 20.17% for Q1 2026.

• In Q1 2026, Net Margin fell 653.0% year-over-year to 20.17%; the TTM figure through Mar 2026 stood at 29.65% (down 229.0% YoY), while the FY2025 annual figure was 31.41%, up 34.0% from the prior year.
• Net Margin was 20.17% for Q1 2026 at Regeneron Pharmaceuticals, down from 21.74% in the prior quarter.
• In the past five years, Net Margin ranged from a high of 1947.0% in Q1 2022 to a low of 20.17% in Q1 2026.
• Historically, Net Margin has averaged 212.23% across 5 years, with a median of 30.66% in 2023.
• The sharpest annual moves came in 2022 and 2023: Net Margin soared 190290 bps in 2022, then tumbled 192114 bps in 2023.
• A 5-year view of Net Margin shows it stood at 1197.1% in 2022, then plunged by 97 bps to 33.77% in 2023, then dropped by 28 bps to 24.22% in 2024, then decreased by 10 bps to 21.74% in 2025, then dropped by 7 bps to 20.17% in 2026.
• The last three Net Margin figures came in at 20.17% (Q1 2026), 21.74% (Q4 2025), and 38.89% (Q3 2025), per Business Quant data.